EGALLOHIT GEL IN PATIENTS WITH LASER-INDUCED THERMOTHERAPY OF SUPERFICIAL AND MICRONODULAR BASALIOMA

Cover Page


Cite item

Full Text

Abstract

Background: In basalioma, facial skin is frequent- E-mail: mmacosmetology@mail.ru ly affected. Thus, good cosmetological effect of treatment and anti-tumor efficacy are both important. Optimal approach includes prevention of pathological scarring. In many cases, preventive measures ensure normal scarring even after invasive methods of treatment. Aim: To assess efficacy and safety of Egallohit gel and its effects on scarring in patients with laser-induced thermotherapy (LITT) of basalioma. Materials and methods: 42 patients with superficial and micronodular basaliomas were included. LITT is a new highly effective and less invasive method providing satisfactory cosmetic results. Comprehensive treatment involved LITT (1 or 2 cycles) with subsequent application of Egallohit gel (up to 30 days after the intervention). Results: After the first LITT, clinical cure of basalioma was demonstrated in 41  (97.6%) patients. In one patient with superficial basalioma clinical cure was achieved after the second cycle of LITT. After epithelization of the tumor site, excellent and good clinical result was observed in 15 (35.7%) and 22 (52.5%) patients, respectively (satisfactory results were found only in 5 cases (11,8%), p<0,05). According to the Likert scale scores, 40  patients (95.2%) were very satisfied and 2  patients (4.8%) were satisfied with the treatment. Conclusion: Adding Egallohit after LITT in patients with basaliomas resulted in reduction of connective tissue growth in the lesions, promoted scar tissue resolution and surface smoothening (especially during scar formation), inhibited hyperemia and pigmentation and improved elasticity and displaceability of surrounding tissues.

About the authors

E. I. Tret’yakova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
MD, PhD, Research Associate, Dermatovenereology and Dermato-Oncology Department Россия

T. E. Sukhova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: fake@neicon.ru
MD, PhD, Senior Research Associate, Dermatovenereology and Dermato-Oncology Department Россия

O. V. Matveeva

I.M. Sechenov First Moscow State Medical University; 8/2 Trubetskaya ul., Moscow, 119991,
Russian Federation

Author for correspondence.
Email: mmacosmetology@mail.ru
MD, PhD, Associate Professor, Department of Skin and Venereal Diseases, Institute for Professional Education Россия

References

  1. Сергеев ЮВ, Борисова СВ, Шубина СИ. Актуальные проблемы практической дерматоонкологии: рост заболеваемости, совершенствование диспансеризации и профилактика базальноклеточного рака кожи. Российский журнал кожных и венери-ческих болезней. 1999;(1):8–12.
  2. (Sergeev YuV, Borisova SV, Shubina SI. [Actual problems of practical dermato-oncology: growing disease incidence, improving dispensarization and prevention of basal cell skin cancer]. Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. 1999;(1):8–12. Russian).
  3. Снарская ЕС, Молочков ВА. Базалиома. М.: Медицина; 2003. 136 с.(Snarskaya ES, Molochkov VA. Basal cell carcinoma. Moscow: Meditsina; 2003. 136 p. Russian).
  4. Roseeuw D, Katsambas AD, Hachem JP. Карцинома базально-клеточная. В: Кацамбас АД, Лотти ТМ, ред. Европейское руководство по лечению дерматологических болезней. М.: МЕДпресc-информ; 2008. c. 199–211. (Roseeuw D, Katsambas AD, Hachem JP. Basal cell carcinoma. In: Katsambas AD, Lot-ti TM, European handbook of dermatological treatments. Moscow: MEDpress-inform; 2008. p. 199–211. Russian).
  5. Raasch B. Management of superficial basal cell carcinoma: focus on imiquimod. Clin Cosmet Investig Dermatol. 2009;2:65–75.
  6. Молочков ВА, Молочков АВ. Клиническая дерматоонкология. М.: Студия МДВ; 2011. 340 c.
  7. (Molochkov VA, Molochkov AV. Clinical Dermato-Oncology. Moscow: Studiya MDV; 2011. 340 p. Russian).
  8. Daudén E; BASALE Study Group. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. J Eur Acad Dermatol Venereol. 2011;25(11):1304–10.
  9. Ключарева СВ, Нечаева ОС, Курганская ИГ. Патологические рубцы в практике дермато-косметолога: новые возможности терапии препаратом «Галадерм». Вестник эстетической медицины. 2009;8(2):41–9. (Klyuchareva SV, Nechaeva OS, Kurganskaya IG. [Pathological scars in dermatologists & cosmetologist`s practice: new Galaderm preparation therapy possibilities]. Vestnik es-teticheskoy meditsiny. 2009;(2):41–9. Russian).
  10. Юсупов АС. Исследование эффективности и безопасности эпигаллокатехин-3-галлата (крем галадерм) при проведении фотодинамической терапии базальноклеточного рака кожи. Клиническая дерматология и венерология. 2008;(4):73–8. (Yusupov AS. [A study of efficacy and safety of epigallocatechin-3-gallate (Galaderm cream) in a photodynamic therapy of basal-cell cancer of the skin]. Klinicheskaya dermatologiya i venerologiya. 2008;(4):73–8. Russian).
  11. Nemeth AJ. Keloids and hypertrophic scars. J Dermatol Surg Oncol. 1993;19(8):738–46.
  12. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2001;280(1):E75–82.
  13. Lee YS, Vijayasingam S. Mast cells and myofibroblasts in keloid: a light microscopic, immunohistochemical and ultrastructural study. Ann Acad Med Singapore. 1995;24(6):902–5.
  14. Szasz A, Vincze G. Dose concept of oncological hyperthermia: heat-equation considering the cell destruction. J Cancer Res Ther. 2006;2(4):171–81.
  15. Zhang Q, Kelly AP, Wang L, French SW, Tang X, Duong HS, Messadi DV, Le AD. Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. J Invest Dermatol. 2006;126(12):2607–13.
  16. Сизов ВМ. О механизме образования пато-логических рубцов. Клиническая хирургия. 1990;(3):51–4. (Sizov VM. [On the mechanism of pathological scarring]. Klinicheskaya khirurgiya. 1990;(3):51–4. Russian).
  17. Rhodes LE, de Rie M, Enström Y, Groves R, Morken T, Goulden V, Wong GA, Grob JJ, Varma S, Wolf P. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17–23.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Tret’yakova E.I., Sukhova T.E., Matveeva O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies